Illumina Revenue Decline, And Other News: The Good, Bad And Ugly Of Biopharma

Illumina Inc. (ILMN) reported its second quarter financial results. However, due to various factors including the pandemic outbreak, the numbers were not too good. The company also provided updates about business operations including new appointments and capital expenditures. Illumina has already announced the withdrawal of its fiscal 2020 full-year revenue and earnings per share guidance.

Illumina reported its revenue for the second quarter at $633 million, down 25 percent on a year over year basis. The company had reported $838 million in revenue for the second quarter of the previous year. Its GAAP adjusted net income attributable to shareholders was reported at $47 million, down from $296 million for the corresponding quarter of the previous year. On a per share basis, GAAP net income for the second quarter was $0.32 per diluted share.

Illumina announced its non-GAAP net income at $92 million or $0.62 per diluted share, down from $200 million on a year over year basis. Its cash flow from operations was $240 million compared to $143 million in the second quarter of 2019. The previous year's figure included an $84 million payment of the accreted debt discount related to the conversion of 2019 Notes.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.